Pharmaceutical

EC approves AstraZeneca’s Calquence combo to treat MCL

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) combo.

May 8, 2025 - 06:00
EC approves AstraZeneca’s Calquence combo to treat MCL
The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) combo.
Read the original article

Tags:

Previous Article

Expediting parallel drug approval pathways is challenging, but rewarding

Next Article

Overcoming challenges in orphan drug development: From clinical trials to market

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT+: AbbVie purchases neuroscience developer Cerevel ...

Dec 7, 2023

STAT+: Carbon Health blasts a major insurer in rare public dispute over coverage

STAT+: Carbon Health blasts a major insurer in rare pub...

May 1, 2023

STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs

STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; k...

Jul 26, 2023